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Abstract
Background: Although Temozolomide is effective against glioblastoma, the prognosis remains
dismal and new regimens with synergistic activity are sought for.
Methods:  In this phase-I/II trial, pegylated liposomal doxorubicin (Caelyx™, PEG-Dox) and
prolonged administration of Temozolomide in addition to radiotherapy was investigated in 63
patients with newly diagnosed glioblastoma. In phase-I, PEG-Dox was administered in a 3-by-3
dose-escalation regimen. In phase-II, 20 mg/m2 PEG-Dox was given once prior to radiotherapy and
on days 1 and 15 of each 28-day cycle starting 4 weeks after radiotherapy. Temozolomide was given
in a dose of 75 mg/m2 daily during radiotherapy (60 Gy) and 150-200 mg/m2 on days 1-5 of each
28-day cycle for 12 cycles or until disease progression.
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Results:  The toxicity of the combination of PEG-Dox, prolonged administration of
Temozolomide, and radiotherapy was tolerable. The progression free survival after 12 months
(PFS-12) was 30.2%, the median overall survival was 17.6 months in all patients including the ones
from Phase-I. None of the endpoints differed significantly from the EORTC26981/NCIC-CE.3 data
in a post-hoc statistical comparison.
Conclusion: Together, the investigated combination is tolerable and feasible. Neither the addition
of PEG-Dox nor the prolonged administration of Temozolomide resulted in a meaningful
improvement of the patient's outcome as compared to the EORTC26981/NCIC-CE.3 data
Trial registration: clinicaltrials.gov NCT00944801.
Background
Glioblastomas represent 40% of all tumors of the central
nervous system (CNS) and are among the most lethal
tumors. Therapy comprising debulking surgery and radio-
therapy prolongs the median overall survival after initial
diagnosis to only 8-12 months [1,2]. Temozolomide
(Temodar™, TMZ) combined with radiotherapy was the
first substance to significantly improve the overall survival
(to 14.6 months) as compared to surgery and radiother-
apy alone and increased the proportion of patients surviv-
ing more than 2 years to 26%. TMZ showed the best
efficacy in patients with a methylated O6-methylguanine-
DNA methyltransferase (MGMT) promoter by eliminat-
ing more sensitive differentiated tumor cells and in part
stem cell-like tumor cells [3,4]. Among patients with a
methylated MGMT promoter, the median survival after
treatment with combined radio-chemotherapy was 21.7
months, as compared to 15.3 months among those who
were assigned to radiotherapy only. In the absence of
methylation of the MGMT promoter, there was a smaller
and statistically insignificant difference in survival
between the treatment groups [4].
Doxorubicin is one of the most effective substances in vitro
against cells derived from glioblastoma [5]. However, it
has no significant effect in vivo due to poor blood-brain-
barrier penetration [6]. In a tumor model, tissue and CSF-
concentrations of doxorubicin were substantially
increased when sterically stabilized liposomes were used
[7] resulting in a comparable clinical response using
approximately half of the dose of stabilized liposomes
compared to conventional doxorubicin [8]. A pegylated
formulation (PEG-liposomal Doxorubicin, Caelyx™, PEG-
Dox) even further improved the penetration of the blood-
brain barrier [9]. Case series and two phase II-studies in
patients with recurrent glioblastoma have shown mod-
estly promising results for PEG-Dox [10-13]. In our
cohort, we treated 27 patients with recurrent glioblastoma
with 20 mg/m2 PEG-Dox on days 1 and 15 of each 28-day
cycle. The overall response rate was 39%. The progression
free survival at 6 and 12 months after initiation of therapy
was 15% and 7.5%, and median time to tumor progres-
sion for responders was 14 weeks, respectively. Median
overall survival was 68 weeks after initial diagnosis and 26
weeks after initiation of the relapse regimen [11].
Based on these results, we combined PEG-Dox, TMZ, and
radiotherapy in the study presented here, adapting the
standard of care EORTC26981/NCIC-CE.3 protocol.
Because long-term administration of TMZ for more than 6
cycles (as used in the EORTC26981/NCIC-CE.3 trial) is
feasible and well tolerated [14], we decided to administer
TMZ for at least 12 cycles or until disease progression. To
determine the dose limiting toxicity of PEG-Dox com-
bined with prolonged administration of TMZ, we per-
formed a phase I part ahead of the phase II study. To
investigate, by means of a historical control analysis, if the
addition of PEG-Dox to TMZ and radiotherapy improves
the survival of patients, we chose similar inclusion criteria
and identical TMZ and radiotherapeutic regimes as in the
EORTC26981/NCIC-CE.3 study.
Methods
Patients and Selection Criteria
From June 2002 until November 2007, 63 patients with
newly diagnosed glioblastoma in two neurooncology
centers (Department of Neurology, University of Regens-
burg, Germany and Department of Neurology, University
of Innsbruck, Austria) were selected for the study (Figure
1). Eligible patients aged 18 to 70 with centrally con-
firmed histology (Institute for Neuropathology, Univer-
sity of Bonn, Germany) were included. Inclusion criteria
were adapted to the EORTC26981/NCIC-CE.3 study and
were, among others, as follows: Karnofsky performance
score (KPS) ≥ 70%, stable corticosteroids within 2 weeks
before inclusion, leucocytes > 3/ul, thrombocytes > 100/
ul, Hb > 10 g/dl. The study was approved by the ethics
committees of the participating centers, and was per-
formed in accordance to the applying international regu-
lations. All patients provided written informed consent.
The trial was registered at clinicaltrials.gov:
NCT00944801.BMC Cancer 2009, 9:308 http://www.biomedcentral.com/1471-2407/9/308
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Study Design and Treatment
Within 4 weeks after the histological diagnosis of glioblas-
toma, all patients received standard radiotherapy (total
dose 60 Gy; fractions of 2 Gy Monday to Friday) plus con-
comitant daily TMZ 75 mg/m2 orally daily (including
weekends). Radiotherapy was planned with dedicated
computed tomography and three-dimensional planning
systems and delivered to the gross tumor volume with a 2
to 3 cm margin for the clinical target volume. After a 4-
week break, patients received adjuvant TMZ 150 to 200
mg/m2 day 1 to 5 in 28 days until tumor progression or up
to at least 12 cycles [2]. In the dose escalation phase of the
study, PEG-Dox was raised in steps of 5 mg/m2 in a 3-by-
3 design, starting with 5 mg/m2 (group 1) up to 20 mg/m2
(group 4). In the phase II part of the study, the targeted
dose of 20 mg/m2 was administered up to a cumulative
dose of 550 mg/m2 or until tumor progression.
CONSORT flow diagram Figure 1
CONSORT flow diagram.BMC Cancer 2009, 9:308 http://www.biomedcentral.com/1471-2407/9/308
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The following events were defined as dose limiting toxic-
ity (DLT) occurring within the first cycle of adjuvant treat-
ment and graded according to the National Cancer
Institute Common Toxicity Criteria, version 3.0 (NCI-
CTC 3.0): myelosuppression, palmoplantar erythrodys-
esthesia (PPED), cardiac, hepatic or renal toxicity grade 3
or 4; and every severe adverse event (SAE) as long as a cor-
relation to the study medication was at least "possible"
using standard SAE grading criteria. Each dose level was
evaluated for DLTs using the criteria detailed above before
advancing to the next level. In both parts of the study, the
dosing of TMZ and PEG-Dox was modified as follows: If
myelotoxicity of grade 3 or 4 occurred, the next cycle of
chemotherapy was delayed, and the dose was reduced to
75% in the next cycle. If grade 4 myelotoxicity recurred
after dose reduction or persisted for more than four weeks,
treatment was terminated. All patients received trimetho-
prim-sulfamethoxazole as prophylaxis against Pneumo-
cystis jiroveci pneumonia during concomitant treatment
with radiotherapy plus TMZ.
Surveillance and follow-up
The baseline examination included magnetic resonance
imaging (MRI, minimum T1, T1 plus gadolinium and
FLAIR), full blood counts and blood chemistry tests, and
a physical examination. During radiotherapy, patients
were seen weekly. Transthoracic echocardiography was
performed before the first application of PEG-Dox and at
every 4th cycle of the maintenance chemotherapy. During
and after radiotherapy, full blood counts were drawn
every week until termination of the regimen. 28 days after
the completion of radiotherapy and every 8 weeks there-
after, clinical data and KPS were raised prior to every cycle
throughout the study, until the tumor progressed. Patients
in whom toxicity precluded further treatment were closely
followed up until resolution or stabilization of the respec-
tive condition. Standard supportive care measures were
thoroughly applied in addition to chemotherapy. At
tumor progression, patients were treated at the investiga-
tor's discretion. The therapeutic modalities used in recur-
rent disease included re-resections, re-radiotherapy, and
salvage chemotherapy (e.g. CCNU, and Imatinib Mesylate
based chemotherapies).
Evaluation of Toxicity and Activity
Tumor progression was defined according to Macdonald
criteria [15]. Toxicity (dose limiting toxicity, DLT, and tar-
geted dose) graded according to NCI-CTC 3.0 in phase I
and progression free survival at 12 months (PFS-12) after
initiation of therapy in phase I and II were defined as the
primary endpoints of the study; PFS-24, median overall
survival (mOS), overall survival after 1 and 2 years (OS-
12, OS-24), median time to progression (mTTP), response
rate (RR, complete responses plus partial responses), rate
of stabilizations (SD, stable disease), and the toxicity pro-
file were secondary endpoints.
MGMT Evaluation
The  MGMT  methylation status was determined by the
classic gel based methylation specific PCR (MSP) assay [4]
and a high throughput quantitative MSP technique
(qMSP) as part of a validation study [16].
Statistical Methods
The study was planned on an adapted intent-to-treat-
design. An interim analysis was performed after phase I
(termination criterion: unacceptable toxicity) of the study
and after treating 10 patients in phase II (termination cri-
terion: tumor progression within 10 weeks in more than 8
patients). The primary endpoint of the study was progres-
sion free survival probability at 12 months starting at the
time of diagnosis. The trial was designed to accrue 60
patients (plus 5% drop-out reserve) with glioblastoma
and to detect an improvement of the PFS-12 of 15.6% as
compared to the data of the EORTC26981/NCIC-CE.3
(radiotherapy plus concomitant and adjuvant TMZ) arm
(PFS-12: 26.9%) with an α error of 0.10 and β error of
10%. The exact patient number was determined during
study accrual after publication of the EORTC26981/
NCIC-CE.3 trial in 2005. Based on a Fleming design, the
hypothesis tested was H0:PFS-12 ≤ 26.9% and H1: PFS-12
≥ 42.5% The minimum PFS-12 to consider the study as
"positive" was 36.7%.
As this trial was not randomized, the EORTC26981/
NCIC-CE.3 data were used as historical controls and the
Cox proportional hazard model was fit to directly assess
the effect of the new treatment measured by their Hazard
Ratios (HR) in presence of known prognostic factors (age,
KPS, extent of surgical resection, corticosteroids at begin-
ning of therapy) in order to correct for selection biases.
HR, median PFS and OS, PFS-12, OS-12, and OS-24 were
assessed in all patients and in subsets split by MGMT
methylation status. The Cox proportional hazard model
was fit to assess the prognostic value of the methylation
status of the MGMT promoter in combination with the
protocol treatment modalities.
Results
Patient Characteristics
In total, 70 patients were screened and 63 patients (40
male, 23 female) with newly diagnosed glioblastoma
were included and evaluable according to the intent-to-
treat design (Figure 1). Median age was 54 years (range:
30-73) and 40% were older than 60 years. The median
KPS at inclusion was 90% (range: 70-100%) for the total
population; 29% of the patients were on steroids at entry
into the study (Table 1).BMC Cancer 2009, 9:308 http://www.biomedcentral.com/1471-2407/9/308
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51 patients (81%) had undergone open surgery at primary
diagnosis, aiming at maximum tumor removal. All
patients received conventional involved-field radiother-
apy with a total dose of 60 Gy and concomitant TMZ (75
mg/m2 daily, every day including weekends) during radi-
otherapy. Three of the patients did not complete the com-
bined radio-chemotherapy due to progressive disease or
were lost for follow-up but were included in the analysis
due to the intent-to-treat design.
The most important prognostic risk factors (age, KPS,
extent of resection, corticosteroids at entry) did only mod-
erately differ between this study and the EORTC26981/
NCIC-CE.3 trial (Table 1). Based on sufficient patient
numbers, we concluded that a comparison of our data to
the EORTC26981/NCIC-CE.3 trial was feasible.
Toxicity of the combination regimen
During phase I, the escalation groups consisted of 7 (5
mg/m2 PEG-Dox), 4 (10 mg/m2), 3 (15 mg/m2) and 4 (20
mg/m2) patients. One grade 4 leukopenia and neutrope-
nia occurred in the first group within 3 months after diag-
nosis which was therefore expanded from 4 to 7 patients
in accordance to the treatment plan. In the 2nd, 3rd and 4th
treatment groups, the regimen was tolerated without DLT.
As no DLT was observed in dose group 4, the targeted dose
was reached and we proceeded to the efficacy phase of the
trial with PEG-Dox in a dose of 20 mg/m2.
Table 1: Baseline characteristics of the RNOP-09 cohort as compared to the patients enrolled into the EORTC 26981/NCIC-CE.3 
trial.
Baseline characteristics
Treatment
RNOP-09
(N = 63)
EORTC/NCI-C/NCI-C
(N = 287)
N (%) N (%)
Sex
Female 23 (36.5) 102 (35.5)
Male 40 (63.5) 185 (64.5)
Age (class)
<= 50 19 (30.2) 95 (33.1)
51-60 19 (30.2) 109 (38.0)
>60 25 (39.7) 83 (28.9)
Performance status (KPS)
90-100% 22 (34.9) 113 (39.4)
80% 33 (52.4) 136 (47.4)
70% 8 (12.7) 38 (13.2)
Extent of surgery
Complete 28 (44.4) 113 (39.4)
Partial 23 (36.5) 126 (43.9)
Biopsy 9 (14.3) 48 (16.7)
Not recorded 3 (4.8) 0 (0.0)
Corticosteroids at study entry
No 39 (61.9) 94 (32.8)
Yes 18 (28.6) 193 (67.2)
Missing data 6 (9.5) 0 (0.0)
MGMT promoter
Methylated 16 (25.4) 46 (16.0)
Unmethylated 17 (27.0) 60 (20.9)
Missing 30 (47.6) 181 (63.1)
Survival at evaluation
Alive 22 (34.9) 33 (11.5)
Dead 41 (65.1) 254 (88.5)
Progression free survival at evaluation
Not progressive and alive 7 (11.1) 15 (5.2)
Progressive or dead 56 (88.9) 272 (94.8)BMC Cancer 2009, 9:308 http://www.biomedcentral.com/1471-2407/9/308
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In the summarized toxicity data from phase I and II, the
most frequent adverse event attributable to PEG-Dox was
palmaroplantar erythrodysesthesia (PPED) occurring in
almost all patients to at least some degree. Still, severe
cutaneous side effects were rare. During the administra-
tion of 402 PEG-Dox infusions, grade 3 or 4 toxicities -
defined as bullous exanthema - were seen in only 4
patients. Occurrence of PPED was reduced by oral pyri-
doxine in a daily dose of 3 × 100 mg, low-dose oral corti-
costeroids, and cool pads during the infusion of PEG-Dox
[17]. The most common side effect attributable to a com-
bined effect of TMZ and PEG-Dox was myelosupression
(Table 2). Grade 3 to 4 leukopenia was observed in 12
patients (19%, EORTC26981/NCIC-CE.3: 7%), grade 3
and 4 thrombocytopenia occurred in 7 patients (11%,
EORTC26981/NCIC-CE.3: 12%). Grade 3 and 4 lympho-
penia, the most common haematologic toxicity, occurred
in 33 patients (52%, EORTC26981/NCIC-CE.3: no data
available). Despite this high proportion of lymphopenia,
only two patients suffered from opportunistic Pneumo-
cystis jierovici pneumonia (one NCI-CTC 3.0 grade 4
event), while 7 patients (15.2%) were treated with com-
munity-acquired pneumonia that was only possibly
related to the ongoing chemotherapy. As in the other pub-
lished studies with PEG-Dox in high-grade gliomas [10-
13], we did not observe cardiotoxic side effects, even in
cases with cumulative doses of up to 550 mg/m2. Two
patients developed deep vein thrombosis. Overall, 58
SAEs occurred, and 9 of these SAEs were at least possibly
related to PEG-Dox. Two patients died due to a possibly
treatment-related complication (one pulmonary embo-
lism, one unclear rapid decline in general condition). The
toxicity data are summarized in Table 2.
Activity of the combination regimen
All patients were observed until progression after treat-
ment initiation. One patient was lost to follow-up, and his
data were included in the statistical analysis using the last
Table 2: Side effects of the combined radio-chemotherapy with TMZ and PEG-Dox.
Treatment related toxicity **
Common toxicity criteria (NCI CTC Version 3.0)
RNOP-09
Grade 3
RNOP-09
Grade 4*
EORTC/NCI-C
Grade 3+4
N (%) N (%) N (%)
Gastrointestinal
Vomitus/nausea 4 (6.3) 0 (0.0) 6 (2)
Stomatitis 2 (3.2) 0 (0.0) not reported
Gastritis 2 (3.2) 0 (0.0) not reported
Diarrhea 3 (4.8) 0 (0.0) not reported
Skin
PPED/rash 4 (6.3) 0 (0.0) 9 (3)
Herpes simplex infection 2 (3.2) 0 (0.0) not reported
Edema 2 (3.2) 0 (0.0) not reported
Anaphylaxis 0 (0.0) 1 (1.5) not reported
Infection
Pneumonia 8 (12.7) 1 (1.5) not reported
Wound infection 1 (1.5) 0 (0.0) not reported
not specified 9 (14.2) 0 (0.0) 20 (7)
Blood/bone marrow
Leukopenia 9 (14.3) 3 (4.7) 20 (7.0)
Lymphopenia 6 (9.5) 27 (43.9) not reported
Thrombopenia 4 (6.3) 3 (4.7) 33 (12.0)
Anemia 0 (0.0) 2 (3.2) 4 (1.0)
Cardiac and vascular toxicity
Cardiac toxicity 0 (0.0) 0 (0.0) not reported
Deep vein thrombosis 2 (3.2) 0 (0.0) not reported
Pulmonary embolism 0 (0.0) 1 (1.5) not reported
* Two additional patients died, one due to pulmonary embolism and une due to unclear decline in general condition (CTC grade 5).
** Side effects are listed irrespective if they were related to the therapy.BMC Cancer 2009, 9:308 http://www.biomedcentral.com/1471-2407/9/308
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date of observation. PFS-12 as primary endpoint was
30.2% as compared to 26.9% for patients treated with
combined radio-chemotherapy in the EORTC26981/
NCIC-CE.3 study (adjusted HR for progression free sur-
vival: 0.91; CI: 0.67-1.26; p = 0.58). The OS-24 was 35.3%
(EORTC26981/NCIC-CE.3: 27.2%), the mOS was 17.6
months (EORTC26981/NCIC-CE.3: 14.6 months), and
the adjusted HR for overall survival was 0.79 (CI: 0.55-
1.14; p = 0.21, Figure 2). Complete response during the
protocol therapy including radiotherapy and chemother-
apy (CR, n = 2), partial response (PR, n = 3) or stable dis-
ease (SD, n = 41) were observed in 73% of patients 8
weeks after initial diagnosis. 8 weeks after initiation of the
maintenance therapy (i.e. 20 weeks after tumor resection),
34 patients (53%) were free of progression [18]. There was
no significant difference between patients that received
less than 20 mg/m2 PEG-Dox in the phase I part of the
study and the patients treated with 20 mg/m2 [see Addi-
tional File 1]. All other endpoints are summarized in
Table 3. Of note, the combination of PEG-Dox, prolonged
TMZ, and radiotherapy was significantly superior to radi-
otherapy alone with respect to overall survival and PFS-12
(30.2% vs. 9.1%; p < 0.002) confirming previous results
[2] (data not shown).
MGMT methylation status and correlation with tumor 
progression and survival
The MGMT methylation status could be determined in 33
patients (52%). The samples with assignable MGMT pro-
moter status were representative of the overall treatment
population with respect to prognostic factors and out-
comes except for a slight imbalance in the resection status
(patients with determined MGMT promoter status had
less biopsies, data not shown). Of the evaluated tumors,
16 (48%) had detectable MGMT promoter methylation,
whereas 17 (52%) did not. The proportion of MGMT
methylated and unmethylated tumors is similar to previ-
ous studies [4]. With respect to all analyzed endpoints,
there were no statistically significant differences between
both groups. However, the statistical power of this study
was too low to allow final conclusions (Table 3).
Discussion
This is the first phase II-trial to evaluate the activity of
PEG-Dox and prolonged administration of TMZ in addi-
tion to standard radio-chemotherapy in the first-line treat-
ment of patients with glioblastoma. Our data were
compared to the standard-of-care established in the
EORTC26981/NCIC-CE.3 trial by means of a historical
control analysis to disclose superiority of our combined
approach. In this multi-institutional trial, we could show
that neither the addition of PEG-Dox (20 mg/m2 day 1
and 15 of 28 days) nor the prolonged administration of
TMZ to standard therapy comprising TMZ and radiother-
apy meaningfully improves PFS-12 in comparison to the
EORTC study. However, the study was not formally pow-
ered to evaluate long-term survival. Although the com-
bined therapy slightly increased the median overall
survival of the total study population to 17.6 months as
compared to 14.6 in the EORTC26981/NCIC-CE.3 study
[2], this difference did not reach statistical significance.
Agreed confidence intervals of medians were largely over-
lapping (RNOP-09: median 14.6; CI: [13.2-16.8] -
EORTC26981/NCIC-CE.3: median: 17.6; CI: [12.2-
22.7]). In addition, 73% of all patients had objective
responses or stabilizations according to Macdonald's cri-
teria [15].
The overall toxicity pattern was acceptable over the study
course. As expected, the most common adverse effect
clearly attributable to PEG-Dox was palmaroplantar
erythrodysesthesia (PPED). The relatively high incidence
of PPED under therapy with PEG-Dox may be explained
by accumulation of liposomes in the small capillaries of
the skin [19,20]. Higher grade toxicity was rare due to
extensive supportive care measures [17] and in line with
previous studies suggesting that skin toxicity occurs more
frequently if the dose exceeds 60 mg/m2  per month
[20,21]. Hematological side effects were pronounced as
compared to the EORTC26981/NCIC-CE.3 study and
possibly caused more infectious complications. Although
the data cannot be compared directly as they were evalu-
ated in different study populations, they suggest that the
addition of PEG-Dox and/or prolonged administration of
TMZ increased the myelotoxicity of TMZ moderately. Still,
the overall toxicity profile remained favorable. In line
with previous reports, cardiotoxicity did not occur [22].
Overall survival of RNOP-09 patients as compared to histor- ical control Figure 2
Overall survival of RNOP-09 patients as compared to 
historical control. Kaplan-Meier estimates of overall sur-
vival according to treatment group. The unadjusted hazard 
ratio for death among patients treated with PEG-Dox and 
prolonged administration of TMZ as compared with those 
treated in the EORTC26981/NCIC-CE.3 trial was 0.83 (CI: 
0.60-1.16; p = 0.28).
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Although unknown biasing factors cannot be excluded
due to the lack of randomization, our data allow final
conclusions because of the large patient population (63
patients), the statistical design (power of 90% to detect a
meaningful improvement of PFS-12), and the well bal-
anced patient populations of RNOP-09 and the
EORTC26981/NCIC-CE.3 study. The slight increase of
long term survivors is low as compared to other phase II
studies [23] but may also reflect minor differences in the
patients characteristics (e.g. low proportion of patients on
steroids at entry). Thus, it is unlikely that a larger patient
population, e.g. in a Phase III-setting, would unveil a clin-
Table 3: Primary and secondary endpoints of the RNOP-09 study as compared to the EORTC26981/NCIC-CE.3 trial.
EORTC/NCI-C
(N = 287)
RNOP-09
(N = 63)
All patients
Progression Free Survival
Median duration (mo) 6.9 (5.8-8.2) 6.5 (6.0-8.3)
Rate at 1 yr (%) † 26.9 (21.9-32.2) 30.2 (19.4-41.6)
Rate at 2 yrs (%) 11.2 (7.9-15.1) 11.0 (4.4-20.9)
Hazard Ratio ‡ 1.00 0.91 (0.67-1.26)
p-value ** P = 0.58
Overall Survival
Median duration (mo) 14.6 (13.2-16.8) 17.6 (12.2-22.7)
Rate at 1 yr (%) 61.2 (55.3-66.6) 60.3 (47.2-71.2)
Rate at 2 yrs (%) 27.2 (22.2-32.5) 35.3 (22.1-48.7)
Hazard Ratio ‡ 1.00 0.79 (0.55-1.14)
p-value ** P = 0.21
MGMT methylation status (N = 106)
(46 meth., 60 unmeth.)
(N = 33)
(16 meth., 17 unmeth.)
Methylated MGMT Promoter
Progression Free Survival
Rate at 1 yr (%) 40.0 (25.8-53.8) 31.3 (11.4-53.7)
Hazard Ratio ‡ 1.00 0.79 (0.39-1.61)
p-value ** P = 0.52
Overall Survival
Rate at 1 yr (%) 77.8 (62.6-87.4) 68.8 (40.5-85.6)
Rate at 2 yrs (%) 48.9 (33.7-62.4) 37.5 (15.4-59.8)
Hazard Ratio ‡ 1.00 0.98 (0.46-2.11)
p-value ** P = 0.97
Unmethylated MGMT Promoter
Progression Free Survival
Rate at 1 yr (%) 13.3 (6.2-23.2) 25.5 (7.3-44.9)
Hazard Ratio ‡ 1.00 1.03 (0.47-2.26)
p-value ** P = 0.94
Overall Survival
Rate at 1 yr (%) 56.7 (43.2-68.1) 41.2 (18.6-62.6)
Rate at 2 yrs (%) 14.8 (7.2-25.0) 16.5 (2.9-39.9)
Hazard Ratio ‡ 1.00 0.93 (0.44-1.95)
p-value ** P = 0.84
* Numbers in parenthesis are 95 percent confidence intervals
† Primary endpoint
‡ Obtained from the Cox model after adjustment of RNOP-09 treatment effect for extent of surgery (B/PR/CR), Age (< = 50,51-60,>60), 
Performance Status (0,1,2), administration of corticosteroids (No/Yes)
** Wald's testBMC Cancer 2009, 9:308 http://www.biomedcentral.com/1471-2407/9/308
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ically meaningful improvement of the PFS-12 or the pro-
portion of long term survivors by PEG-Dox. In addition,
our data does not support prolonged TMZ based chemo-
therapy schedule in non-progressive patients. Although
non-progressive patients were treated in the RNOP-09
trial up to at least 12 cycles of maintenance chemotherapy
with TMZ, this neither translated into a meaningful
improvement of PFS nor mOS, at least summarized over
all patients. The slightly increased toxicity of the com-
bined therapy did not translate into a relevant PEG-Dox
related mortality. Thus it appears unlikely that PEG-Dox
induced toxicity masked the positive effects of prolonged
TMZ administration. With the comparable activity, the
common cutaneous side effects, and the increased rate of
infections this combined therapy did not show sufficient
signs of activity in addition to the EORTC26981/NCIC-
CE.3 protocol to be recommended.
Conclusion
Based on in vitro results, PEG-Dox was among the promis-
ing substances of a large panel of "classical" chemothera-
peutic substances tested in glioblastoma during the last
decades [24]. None of these substances, except TMZ,
could improve the prognosis of glioblastoma in a first-
line setting, and the improvement is largely limited to
patients with a methylated MGMT promoter. Recent trials
that tested dose intensifications of TMZ [25,26] or combi-
nations of different agents with TMZ [23,27] failed to
improve the prognosis of patients with an unmethylated
MGMT promoter. Thus, we suggest that combinations of
classic cytostatic drugs may not be effective to improve the
outcome of these patients. New targeted therapies com-
bined with cytotoxic drugs might be better suitable to
delay progression and improve survival in patients with
an unmethylated MGMT promoter. This hypothesis will
have to be tested in randomized phase II trials, as even
large non-randomized trials might miss clinically mean-
ingful results due to the inappropriate control for
unknown biasing factors beyond the known prognostic
factors. Such studies are in development or started accrual
recently and hopefully will produce relevant improve-
ments for these patients.
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